no more tirzepatide FDA says years-long shortage is resolved, will give limited leeway to compounders Tirzepatide (Zepbound, Mounjaro): Weight Loss,

Continuous GLP-1RA Use Reduces MACE Risk Incident use of GLP-1RAs was associated with a lower risk of MACE compared to incident use of sulfonylureas

The shipping time is great and I have never had a problem

Enrollment criteria and endpoints differ between studies, and individual outcomes vary

Compare them side by side below

In the SURMOUNT trials, tirzepatide at 15 mg averaged 22.5 percent body weight loss over 72 weeks, while the 5 mg and 10 mg doses landed roughly in the 15 to 20 percent range

However, it is thought that it may work by inhibiting the activity of a protein called GLP-1R, which is overexpressed in thyroid cancer cells